g(m1)-ganglioside has been researched along with Burkitt-Lymphoma* in 2 studies
2 other study(ies) available for g(m1)-ganglioside and Burkitt-Lymphoma
Article | Year |
---|---|
An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line.
We have previously demonstrated that an anti-CD19 monoclonal antibody (MAb; HD37) inhibits the function of the P-glycoprotein (P-gp) pump in a multidrug-resistant (MDR) B-lymphoma cell line, Namalwa/MDR1, and that this effect is not due to the recognition of a cross-reactive epitope on P-gp. In this study, we have used the same cell line to define the mechanisms responsible for the effect of HD37 on the P-gp pump. Using fluorescence resonance energy transfer (FRET), we show that CD19 and P-gp are constitutively associated in cells. In the absence of treatment with anti-CD19, 40% of P-gp molecules expressed by Namalwa/MDR1 cells reside in the low-density lipid (ie, cholesterol-rich) microdomains (lipid rafts). Following treatment of the cells with HD37 and disruption of the interactions between P-gp and CD19, P-gp translocated out of lipid rafts and CD19 translocated into lipid rafts. The effect of chemosensitization on Namalwa/MDR1 cells was specific for CD19; an anti-CD22 MAb had no such effect, although the cells express CD22. These results suggest that anti-CD19 might chemosensitize P-gp(+) cells by interfering with interactions between CD19 and P-gp, rapidly resulting in the translocation of P-gp into a compartment on the plasma membrane where it is no longer active. Topics: Antibodies, Monoclonal; Antigens, CD19; ATP Binding Cassette Transporter, Subfamily B, Member 1; Burkitt Lymphoma; Cell Line, Tumor; Cell Membrane; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; G(M1) Ganglioside; Gene Expression; Humans; Membrane Microdomains; Protein Binding; Protein Transport; Rhodamine 123 | 2004 |
Effect of gangliosides on binding, internalization and cytotoxic activity of ricin.
The only gangliosides in Burkitt's lymphoma EB-3 cells is GM3. Treatment of Burkitt's lymphoma EB-3 cells with gangliosides GM1 or GM3 results in their binding to and partial incorporation into the cell membrane. About 25% of cell-associated ganglioside GM1 can interact with the ricin. However, such an increase in the number of binding sites does not enhance but rather decreases the cytotoxic effect of ricin. A similar protective effect was observed when the cells were pretreated with ganglioside GM3. In contrast, the increase in ricin biding sites caused by pretreatment of the cells with neuraminidase was accompanied by increase in ricin cytotoxicity. These differences may be related to observed differences in the rate of ricin-endocytosis by native and ganglioside-treated cells. Topics: Binding Sites; Burkitt Lymphoma; Cell Membrane; Cell Survival; Endocytosis; G(M1) Ganglioside; G(M2) Ganglioside; Gangliosides; Liposomes; Neuraminidase; Ricin; Temperature; Tumor Cells, Cultured | 1990 |